Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 11, 2013

Berg, US Department of Defense partner for prostate cancer research

Biopharmaceutical company Berg has partnered with the US Department of Defense to advance prostate cancer research, as part of a cooperative research and development agreement.

prostate cancer

Biopharmaceutical company Berg has partnered with the US Department of Defense to advance prostate cancer research, as part of a cooperative research and development agreement.

The agreement also includes the Uniformed Services University of the Health Sciences’ (USU) Center for Prostate Disease Research (CPDR) and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF).

The open data-sharing collaboration with the Uniformed Services University and Henry M. Jackson Foundation for the Advancement of Military Medicine is expected to offer a new model for scientific discovery.

Berg co-founder, president and CTO Niven Narain said the CPDR has embarked on one of the most comprehensive prostate cancer research programmes in the world.

"This collaboration is an ideal marriage of the CPDR’s extensive prostate cancer expertise and Berg’s unparalleled ability to drive a deeper level of biological understanding," Narain added.

"Together, we have the potential to change the meaning of a prostate cancer diagnosis, and hopefully prognosis, while exemplifying how industry and government can work together to enact real change in public health."

"Together, we have the potential to change the meaning of a prostate cancer diagnosis, and hopefully prognosis, while exemplifying how industry and government can work together to enact real change in public health."

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

A data-driven approach will be followed by Berg and the CPDR to drive molecular intelligence of prostate cancer by identifying biomarkers and better therapies.

The partnership will leverage Berg’s expertise in computational biology and the Interrogative Biology platform to analyse the prostate cancer data supplied by the CPDR.

The Interrogative Biology platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns.

It is designed to provide physicians with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop relevant formulary, and governments with a data ecosystem for financial modelling of healthcare needs of the population, claimed the company.


Image: Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Gleason pattern 4. H&E stain. Prostate currettings. Photo courtesy of Nephron.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU